Abstract Number: 1831 • 2014 ACR/ARHP Annual Meeting
Monitoring Patients with Rheumatoid Arthritis in Routine Care – Experiences from a Treat-to-Target Strategy Using the Danbio Registry
Background/Purpose: Monitoring patients with rheumatoid arthritis (RA) in clinical practice with regular assessment of disease activity (e.g. DAS28) is recommended as a part of a…Abstract Number: 1046 • 2014 ACR/ARHP Annual Meeting
Modulatory Effect of Adiponectin on Apoptosis and Proliferation of Synovial Fibroblasts from Rheumatoid Arthritis Patients
Background/Purpose We previously reported that adiponectin (AD) is highly expressed in the inflammatory joint of rheumatoid arthritis (RA) patients and closely correlated with progressive bone…Abstract Number: 457 • 2014 ACR/ARHP Annual Meeting
First Confirmation Data of Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan
Background/Purpose: To evaluate the long-term safety of tocilizumab (TCZ) for the treatment of rheumatoid arthritis (RA) in a real-world clinical setting in Japan. Methods: In…Abstract Number: 2477 • 2014 ACR/ARHP Annual Meeting
Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
Background/Purpose Physicians, patients, and payers may have different ideas about what constitutes successful treatment and how treatment goals should be defined for rheumatoid arthritis (RA).…Abstract Number: 1532 • 2014 ACR/ARHP Annual Meeting
Efficacy of the Subcutaneous Formulation of Abatacept/Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
Background/Purpose Abatacept is a selective T cell costimulation modulator indicated for moderately to severely active Rheumatoid Arthritis (RA). Since August 2013 is available in Italy…Abstract Number: 1042 • 2014 ACR/ARHP Annual Meeting
IL-1β and TNF-α Promote Monocyte Viability through the Induction of GM-CSF Expression By Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose Macrophages and synovial fibroblasts (SF) are two major cells implicated in the pathogenesis of rheumatoid arthritis (RA). They can interact in the synovial micro-environment…Abstract Number: 411 • 2014 ACR/ARHP Annual Meeting
ABCB1 and ABCG2 Drug-Efflux Transporters Function and Its Association with Disease Activity in a Cohort of Patients with Rheumatoid Arthritis
Background/Purpose ABCB1 (P-gp) and ABCG2 (BCRP) are part of the adenine triphosphate (ATP)-binding cassette (ABC) transporter proteins. These proteins mediate efflux of drugs from inside…Abstract Number: 2493 • 2014 ACR/ARHP Annual Meeting
Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab
Background/Purpose EULAR recommendations for RA therapy suggest addition of a biologic only if poor prognostic factors such as high disease activity are present. However, low…Abstract Number: 1530 • 2014 ACR/ARHP Annual Meeting
Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis
Background/Purpose Rheumatoid arthritis (RA) is a chronic autoimmune disease which results from a breakdown of immune tolerance. Despite their efficacy current RA therapeutics, including biologic…Abstract Number: 989 • 2014 ACR/ARHP Annual Meeting
Fcgamma Receptor IIb Facilitates Rapid Internalisation of Rituximab (type 1 anti-CD20 antibody) in B Cells from Patients with RA and SLE and Contributes to Less Efficient B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro
Background/Purpose Incomplete B-cell depletion using rituximab (RTX) is associated with poor clinical response in some individuals with RA and SLE, in particular. However, the precise…Abstract Number: 391 • 2014 ACR/ARHP Annual Meeting
Self-Assessment Tool of Rheumatoid Arthritis Disease Activity: Handgrip Strength Measured By a Smartphone Connected to a Dynamometer
Background/Purpose Patient self-management should become a key component of rheumatology care. Development of modalities using personal technologies resources represents an attractive way to assess periodic…Abstract Number: 2458 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments
Background/Purpose The advances in understanding of the molecular nature of immune cell receptors enabled to offer new oral, targeted therapies. Tofacitinib (TOF) is the first…Abstract Number: 1526 • 2014 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy after Multiple Courses of Rituximab in Rheumatoid Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: 3-Year DataÂ
Background/Purpose Efficacy and safety of multiple courses of biologics used over extended periods of time in rheumatoid arthritis (RA) is still a medical debate. The…Abstract Number: 907 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis
Background/Purpose: Ultrasound (US) is sensitive for detecting tenosynovitis in patients with rheumatoid arthritis (RA), where the synovitis can be assessed by grey scale (GS) and…Abstract Number: 368 • 2014 ACR/ARHP Annual Meeting
Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is partly characterized by joint destruction. Personalized health care is needed in RA to enable i) prediction of those patients that…
- « Previous Page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- …
- 56
- Next Page »